Dr. Reddy’s Laboratories’ formulation manufacturing facility at Duvvada, Visakhapatnam, has been audited by the US Food and Drug Administration (USFDA), and the audit has been completed on March 8, 2017. The company has been issued a Form 483 with 13 observations, which it is addressing.
Earlier, the company’s API manufacturing plant at Miryalaguda, had been audited by the USFDA and the audit had been completed on February 21, 2017. The company had been issued a Form 483 with three observations, which it was addressing.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.